Pacific Northwest Society of Pathologists

Size: px
Start display at page:

Download "Pacific Northwest Society of Pathologists"

Transcription

1 Pacific Northwest Society of Pathologists Activity Title: 2009 Spring Meeting Location: Fred Hutchinson Cancer Research Center, Seattle, WA Objectives for this Session Understand the history of medical error disclosure and recent legal developments Identify the error disclosure issues unique to pathology Recognize the relevance of sub-histology of non-small cell lung cancer (NSCLC) in selection of optimal chemotherapy choice for advance NSCLC Understand the potential utility of molecular markers such as ERCC-1, RRM-1, and others in selecting chemotherapy choices for patients with advanced NSCLC Assess the potential value of molecular markers of the epidermal growth factor receptor axis in individualizing treatment recommendations for patients with NSCLC. Identify the pathological features of mesothelioma Identify the use of specialized testing in diagnosing mesothelioma Identify the new approach to neuroendocrine epithelial lung tumors Describe the features of lung allograft rejection Analyze their own lab to identify places where errors occur Define how barcoding technologies can eliminate labeling errors Demonstrate recently described patterns of lung cancer pathology Provide a conceptual framework for understanding bronchiolar pathology and show the correlation between bronchiolar pathology and CT scanning Provide basic knowledge of lung CT for Pathologists and show how CT findings can help in pathologic interpretation Recognize certain lesions of bone that may mimic a sarcoma and recognize histopathological and radiological features that are necessary in distinguishing a pseudosarcomatous tumor from sarcoma Speakers: Thomas Colby, MD, Jack West, MD, Ben Hoch, MD, Mark Wick, MD, Samuel Hammar, MD, Susanne Dintzis, MD, PhD, Rodney Schmidt, MD. Disclosure statements: Yes Overall Program Evaluation: Objectives Objectives Objectives Not Met Met Overall course content Excellent Unsatisfactory Overall program organization Organized Unorganized Your perception of enhanced professional effectiveness Will Enhance Effectiveness Will Not Enhance Effectiveness Materials Organized Unorganized Materials Relevant Not Relevant

2 Mark Wick Benign/Borderline Lung Tumors Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Thomas Colby Lung Cancer Update Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Suzanne Dintzis Disclosing Harmful Pathology Errors to Patients Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Samuel Hammar The Macroscopic, Histologic, Histochemical, Immunohistochemical and Ultrastructural feature of Mesothelioma Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Mark Wick Neuroendocrine Lung Tumors Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent

3 Thomas Colby Bronchiolitis Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Rodney Schmidt Error Reduction Opportunities in the AP Lab Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Thomas Colby Pathologic-Radiologic correlation in Diffuse Lung Disease Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Jack West Individualized Treatment Decisions Based on Pathology Variables in Lung Cancer Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Ben Hoch Diagnostic Challenges in Bone Pathology: Reactive Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent

4 Mark Wick Lung Transplant Reject Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent 1.Please tell us about yourself: A. [ ] MD/DO Specialty: [ ] Administrator/Manager [ ] Other B. Type of organization: [ ] Private practice [ ] Group Practice (# in group ) [ ] IPA/PHO [ ] Hospital Medical Staff [ ] County Medical Society [ ] State Specialty Society [ ] Other 2. To what extent did this course meet your expectation? (Circle one) Exceeded On Target Okay So/So Low 3. Do you feel that the presentation was fair, balanced, and free of commercial bias? If no, please explain. 4. As a result of attending this activity, how will you change your practice? 5. Comments and suggestions: 6. Future topic and speaker suggestions:

5 For CME Credit: Please complete the following only if you are claiming hours less than the maximum. I attended this course: Date: for hours of CME credit. Name (please print) Signature:

Case of the. Month October, 2012

Case of the. Month October, 2012 Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix

More information

Molecular Profiling. Molecular Pathology of Lung Cancer. Lung Cancer Biomarkers. Mutations in Lung Cancer 5/28/2011

Molecular Profiling. Molecular Pathology of Lung Cancer. Lung Cancer Biomarkers. Mutations in Lung Cancer 5/28/2011 Molecular Pathology of Lung Cancer Molecular Profiling Emergence of personalized treatment HER2 receptor-directed therapy in breast cancer with HER2 amplification Recent discovery of genetic alterations

More information

Teaming Up Against Sarcoma

Teaming Up Against Sarcoma Teaming Up Against Sarcoma Recorded on: April 4, 2013 Darin Davidson, MD, MHSc, FRCSC Assistant Professor, Department of Orthopaedics and Sports Medicine University of Washington School of Medicine Robin

More information

New York State Department of Health Clinical Laboratory Standards of Practice. Pathology

New York State Department of Health Clinical Laboratory Standards of Practice. Pathology Pathology Standard All laboratories shall comply with applicable requirements of 10NYCRR Subparts 58-1.12 and 58-1.13. Additionally, the following specialty sustaining standards of practices shall be incorporated

More information

Advances in Lung Cancer: A Multidisciplinary Approach

Advances in Lung Cancer: A Multidisciplinary Approach Advances in Lung Cancer: A Multidisciplinary Approach Saturday, April 25, 2015 127 Public Square Cleveland, Ohio Learning Objectives About the Course This one-day course will provide a topical, clinically

More information

Grading of Bone & Soft Tissue Sarcomas. Ayman Tawil, MD Dept of Pathology & Lab Medicine April 22, 2016

Grading of Bone & Soft Tissue Sarcomas. Ayman Tawil, MD Dept of Pathology & Lab Medicine April 22, 2016 Grading of Bone & Soft Tissue Sarcomas Ayman Tawil, MD Dept of Pathology & Lab Medicine April 22, 2016 Importance of Grading Best predictor of metastasis Crucial to staging Must be assigned to every sarcoma

More information

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care Saturday, April 27, 2013 Cleveland Marriott Downtown at Key Center 127 Public Square Cleveland, Ohio Learning

More information

Current Issues in Surgical Pathology. Thursday-Saturday May 1-3, Register Online at utsouthwestern.edu/cisp. Hyatt Regency Dallas Dallas, Texas

Current Issues in Surgical Pathology. Thursday-Saturday May 1-3, Register Online at utsouthwestern.edu/cisp. Hyatt Regency Dallas Dallas, Texas Current Issues in SPONSORED BY UT Southwestern and the Office of Continuing Medical Education Thursday-Saturday May 1-3, 2014 Hyatt Regency Dallas Dallas, Texas additional information Email: cmeregistrations@utsouthwestern.edu

More information

Guideline Development The American Society of Clinical Oncology

Guideline Development The American Society of Clinical Oncology Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary

More information

Liver Imaging. Liver Imaging/Cirrhosis. Signs of Liver Failure and Portal Hypertension. Methods of Imaging the Liver. CT Workhorse of Imaging

Liver Imaging. Liver Imaging/Cirrhosis. Signs of Liver Failure and Portal Hypertension. Methods of Imaging the Liver. CT Workhorse of Imaging Liver Imaging Patricia Lipford Abbitt,, MD Professor and Chief - Body Imaging Section Department of Radiology College of Medicine University of Florida Liver Imaging/Cirrhosis Number of patients with hepatitis

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Treating Invisible Disease: How the Probability of Disease We Can t See Changes Our Treatment Strategy in Lung Cancer. H.

Treating Invisible Disease: How the Probability of Disease We Can t See Changes Our Treatment Strategy in Lung Cancer. H. Treating Invisible Disease: How the Probability of Disease We Can t See Changes Our Treatment Strategy in Lung Cancer H. Jack West, MD Why should we care about cancer we can t see? Cancer risk is a combination

More information

REVIEW OF LUNG CANCER DIAGNOSIS & THERAPY. CoC Std. 4.6

REVIEW OF LUNG CANCER DIAGNOSIS & THERAPY. CoC Std. 4.6 REVIEW OF LUNG CANCER DIAGNOSIS & THERAPY CoC Std. 4.6 Introduction Lung Cancer remains leading cause of cancer death in both men and women in the US and in Mercer County. Based on American Cancer Society

More information

IDIOPATHIC PULMONARY FIBROSIS

IDIOPATHIC PULMONARY FIBROSIS IDIOPATHIC PULMONARY FIBROSIS Examining the Radiologic-Clinical-Pathologic Correlation Washington Marriott Wardman Park Mezzanine Level Washington, DC 5:30 PM 6:00 PM Registration & Dinner 6:00 PM 7:30

More information

3rd Annual Jefferson Lung Cancer Symposium

3rd Annual Jefferson Lung Cancer Symposium PAID REGISTER ONLINE NOW BY VISITING Jefferson.edu/CME Last Name First Name MI Title (Dr., Mr., Ms.) PERMIT NO. #117 SOUTHEASTERN, PA 19399 at Bluemle Life Sciences Building NON-PROFIT ORG U.S. POSTAGE

More information

Early Detection of Lung Cancer by a FISH-based Sputum Test

Early Detection of Lung Cancer by a FISH-based Sputum Test Early Detection of Lung by a FISH-based Sputum Test US Lung Statistic at Glance Estimated New Cases by Sites, 2015 1 Estimated Deaths by Sites, 2015 1 600,000 480,000 360,000 Prostat e 158,040 240,000

More information

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred

More information

ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival

ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival It is logical that the Cancer Program Committee choose to review the Lung Site, as Lung is the second

More information

Osteolytic metastasis detected by F18-FDG PET in a patient with lung carcinoma

Osteolytic metastasis detected by F18-FDG PET in a patient with lung carcinoma Osteolytic metastasis detected by F18-FDG PET in a patient with lung carcinoma González-Sistal, A 1 ; Baltasar Sánchez, A 1 ; Sánchez Salmón, A 2 ; Ruibal Morell, A 2. 1 Medical Imaging Research Laboratory,

More information

Recruiting now. Could you help by joining this study?

Recruiting now. Could you help by joining this study? Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate

More information

NEWLY CREATED ELECTIVE FOR UPSOM COURSE CATALOG. Name: CLINICORADIOPATHOLOGIC APPROACH TO INTERSTITIAL LUNG DISEASE

NEWLY CREATED ELECTIVE FOR UPSOM COURSE CATALOG. Name: CLINICORADIOPATHOLOGIC APPROACH TO INTERSTITIAL LUNG DISEASE NEWLY CREATED ELECTIVE FOR UPSOM COURSE CATALOG Medical School Elective (MSELCT) Name: CLINICORADIOPATHOLOGIC APPROACH TO INTERSTITIAL LUNG DISEASE Campus/location: UPMC Presbyterian/Montefiore/Falk Slots

More information

Breast Cancer Diagnosis, Treatment and Follow-Up

Breast Cancer Diagnosis, Treatment and Follow-Up Breast Cancer Diagnosis, Treatment and Follow-Up What is Breast Cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide only

More information

If you are signing for a minor child, you refers to your child throughout the consent document.

If you are signing for a minor child, you refers to your child throughout the consent document. CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY Adult Patient or Parent, for Minor Patient INSTITUTE: National Cancer Institute PRINCIPAL INVESTIGATOR: Raffit Hassan, M.D. STUDY TITLE: Tissue Procurement

More information

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. Presenter: Jonathan E. Schwartz, MD

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. Presenter: Jonathan E. Schwartz, MD Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening Disclosures: I, like many physicians, receive compensation from the government and their insurance company cronies who completely

More information

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Outline. Workup for metastatic breast cancer. Metastatic breast cancer Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30

More information

Communication Failures in Dermatopathology: Part 2: Preanalytic 9/15/2015

Communication Failures in Dermatopathology: Part 2: Preanalytic 9/15/2015 Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion of current topics and may be helpful to you in your practice. Today our presentation provides an overview of

More information

Reavis High School Medical Terminology Curriculum Snapshot

Reavis High School Medical Terminology Curriculum Snapshot Reavis High School Medical Terminology Curriculum Snapshot Unit 1: Basic Word Structure Students will analyze words by dividing them into component parts and will utilize suffixes and prefixes and use

More information

Metastatic Cancer: Questions and Answers. Key Points

Metastatic Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Metastatic Cancer: Questions

More information

Diagnostic Slide Session Case Jennifer Ziskin MD, PhD, and Edward D Plowey MD, PhD Stanford University, Stanford, CA

Diagnostic Slide Session Case Jennifer Ziskin MD, PhD, and Edward D Plowey MD, PhD Stanford University, Stanford, CA Diagnostic Slide Session Case 2015-2 Jennifer Ziskin MD, PhD, and Edward D Plowey MD, PhD Stanford University, Stanford, CA Clinical History: 18 year old woman with right facial pain and hyperalgesia Past

More information

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But

More information

Pathology Cytopathology

Pathology Cytopathology Adopted Standard Pathology Cytopathology Adopted Guidance The following specialty sustaining standards of practices shall be incorporated into the laboratory s quality management system, where applicable

More information

An update on the 2015 WHO classification of lung tumors. Jeffrey S. Iding, MD MedStar Franklin Square Medical Center November 20, 2015

An update on the 2015 WHO classification of lung tumors. Jeffrey S. Iding, MD MedStar Franklin Square Medical Center November 20, 2015 An update on the 2015 WHO classification of lung tumors Jeffrey S. Iding, MD MedStar Franklin Square Medical Center November 20, 2015 New Classification: Rationale To address advances in oncology, molecular

More information

Adekunle M Adesina, M.D., Ph.D

Adekunle M Adesina, M.D., Ph.D Adekunle M Adesina, M.D., Ph.D Update of knowledge base is a prerequisite for excellence and maintenance of standards in the practice of medicine Recertification every 7 10years is standard requirement

More information

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer 31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally

More information

Malignant Lesions in Kids: Ewing s Sarcoma and Osteosarcoma. Marco Vennettilli PGY 3 Sept 26, 2007

Malignant Lesions in Kids: Ewing s Sarcoma and Osteosarcoma. Marco Vennettilli PGY 3 Sept 26, 2007 Malignant Lesions in Kids: Ewing s Sarcoma and Osteosarcoma Marco Vennettilli PGY 3 Sept 26, 2007 Outline Presentation Radiology Histology Genetics Treatment and Outcomes Ewing Sarcoma First described

More information

Pre-PET Form National Oncologic PET Registry

Pre-PET Form National Oncologic PET Registry Pre-PET Form National Oncologic PET Registry You have requested a PET scan for an indication for which the Centers for Medicare and Medicaid Services (CMS) requires pre- and post-pet information from the

More information

Plaintiffs Experts Latest Pathological Theories

Plaintiffs Experts Latest Pathological Theories Plaintiffs Experts Latest Pathological Theories Kurt B. Gerstner Campbell Campbell Edwards & Conroy, P.C. One Constitution Center Boston, MA 02129 (617) 241-3086 kgerstner@campbell-trial-lawyers.com Kurt

More information

Pathology Department

Pathology Department Banha University Faculty of Medicine Pathology Department Third Year Student's Guide and Activity Book Student's Name: Student's Number: Group: 00-0 - 0 - Course Specifications University : Benha Faculty

More information

May 18, 2013 Sheraton Delfina Santa Monica, California

May 18, 2013 Sheraton Delfina Santa Monica, California 3rd International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma May 18, 2013 Sheraton Delfina Santa Monica, California Malignant pleural mesothelioma (MPM) is an unusual cancer

More information

Management of GGO and Other Lesions Found on Screening CT Scan

Management of GGO and Other Lesions Found on Screening CT Scan Management of GGO and Other Lesions Found on Screening CT Scan AATS/STS General Thoracic Surgery Symposium American Association for Thoracic Surgery San Francisco, CA April 2012 David R. Jones MD George

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Decoding Breast Cancer Virtual Lab Handbook

Decoding Breast Cancer Virtual Lab Handbook Decoding Breast Cancer Virtual Lab Handbook Decoding Cancer Virtual Lab 2 In precision medicine, physicians consider an individual s specific genes, medical history, environment, and lifestyle. They use

More information

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer

More information

DECEPTIVELY BENIGN- APPEARING PROSTATE CANCER

DECEPTIVELY BENIGN- APPEARING PROSTATE CANCER DECEPTIVELY BENIGN- APPEARING PROSTATE CANCER DISCLOSURE I have nothing to disclose Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, Connecticut FALSE NEGATIVE DIAGNOSES OF MALIGNANCY

More information

A national risk analysis of Norwegian Cancer Care

A national risk analysis of Norwegian Cancer Care A national risk analysis of Norwegian Cancer Care Einar Hannisdal, MD, PhD Nordic Supervision Conference Tromsø May 26th, 2011. Content Why a national risk analysis in Norway? How did we do it? What did

More information

WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14

WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14 WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14 BEFORE: M. Crystal: Vice-Chair HEARING: August 20, 2014 at Toronto Written DATE OF DECISION: December 4, 2014 NEUTRAL CITATION: 2014

More information

Lung Cancer & Mesothelioma 2011-2015

Lung Cancer & Mesothelioma 2011-2015 Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic

More information

2009 Cancer Committee

2009 Cancer Committee 2009 Cancer Committee Lung (non-small cell) Cancer Study Stage IIIA and IIIB John Clouse, M.D. Alicia Stark, RHIT Jeff Robinson Table of Cont ent s Table of Contents... 1 Lung (non-small cell) Cancer Facts.2

More information

Medical Coverage Policy Immunoassay for Tumor Antigens

Medical Coverage Policy Immunoassay for Tumor Antigens Medical Coverage Policy Immunoassay for Tumor Antigens Device/Equipment Drug Medical Surgery Test Other Effective Date: 7/1/2011 Policy Last Updated: 5/7/2013 Prospective review is recommended/required.

More information

Ovarian tumors Ancillary methods

Ovarian tumors Ancillary methods Ovarian tumors Ancillary methods Ovarian tumor course Oslo, 24-25/11/14 Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Division of

More information

Gastrointestinal PATHOLOGY FELLOWSHIP

Gastrointestinal PATHOLOGY FELLOWSHIP Gastrointestinal PATHOLOGY FELLOWSHIP The Department of Pathology and Laboratory Medicine University of Calgary Calgary, Alberta Description and Objectives 2 GASTROINTESTINAL PATHOLOGY FELLOWSHIP Description

More information

Targeted Therapies in Lung Cancer

Targeted Therapies in Lung Cancer Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why

More information

May 18, 2013 Sheraton Delfina Santa Monica, California

May 18, 2013 Sheraton Delfina Santa Monica, California 3rd International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma May 18, 2013 Sheraton Delfina Santa Monica, California Malignant pleural mesothelioma (MPM) is an unusual cancer

More information

PATHOLOGY 101 BLADDER CANCER ADVOCACY NETWORK SEPTEMBER 24 TH, 2001

PATHOLOGY 101 BLADDER CANCER ADVOCACY NETWORK SEPTEMBER 24 TH, 2001 PATHOLOGY 101 BLADDER CANCER ADVOCACY NETWORK SEPTEMBER 24 TH, 2001 Dara L. Aisner, M.D., Ph.D. Assistant Professor, Pathology Co-Director, Colorado Molecular Correlates Laboratory Pathology Myths & Truths

More information

Ardabil Cancer Registry

Ardabil Cancer Registry Cancer Registry Unit of Ardabil Province, Shahrakekarshenasan 1, Aras Clinic, Ardabil, Iran Telfax: 7722636 (+98451) Aras Clinic Ardabil Cancer Registry.......... Annual Report of Cancer Registry Unit

More information

International Journal of Case Reports in Medicine

International Journal of Case Reports in Medicine International Journal of Case Reports in Medicine Vol. 2013 (2013), Article ID 409830, 15 minipages. DOI:10.5171/2013.409830 www.ibimapublishing.com Copyright 2013 Andrew Thomas Low, Iain Smith and Simon

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Training Programme (essential elements) Clinical Practical Year (CPY) at Medical University of Vienna, Austria

Training Programme (essential elements) Clinical Practical Year (CPY) at Medical University of Vienna, Austria Training Programme (essential elements) Clinical Practical Year (CPY) at Medical University of Vienna, Austria CPY-Tertial C Pathology Valid from academic year 2014/15 In charge of the content Ao.Prof.

More information

STAGING IN EARLY BREAST CANCER HELP OR HINDRANCE?

STAGING IN EARLY BREAST CANCER HELP OR HINDRANCE? STAGING IN EARLY BREAST CANCER HELP OR HINDRANCE? Naera Waters Department of Medical Oncology Auckland City Hospital AIMS 1. To assess the frequency of radiological staging in women with early breast

More information

Lung Cancer Treatment Guidelines

Lung Cancer Treatment Guidelines Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,

More information

And also we have Dr. Wally Curran, who is a Radiation Oncologist and Executive Director at Winship Cancer Center at Emory University in Atlanta, GA

And also we have Dr. Wally Curran, who is a Radiation Oncologist and Executive Director at Winship Cancer Center at Emory University in Atlanta, GA Current Concepts & Controversies in Locally Advanced NSCLC, Part 2: Ambiguous Imaging Findings after Chemo/Radiation, with Drs. George Blumenschein and Wally Curran Hello, my name is Jack West, I m a Medical

More information

Clinical Next-Gen Tumor Sequencing:

Clinical Next-Gen Tumor Sequencing: Clinical Next-Gen Tumor Sequencing: Your Key to the Value-Driven Oncology Market Everything you need to know about implementing and optimizing next-gen tumor sequencing at your lab. The demand for oncology-specific

More information

DIFFICULTIES IN THE PATHOLOGIC DIAGNOSIS OF LUNG CANCER Notice of Financial Disclosures (TV Colby MD) (Esp. in small biopsies) Personal Experience Thomas V. Colby, M.D. Mayo Clinic Arizona NONE This talk

More information

Hepatocellular Carcinoma: What the hepatologist wants to know

Hepatocellular Carcinoma: What the hepatologist wants to know Hepatocellular Carcinoma: What the hepatologist wants to know Hélène Castel, MD Liver Unit Hôpital St-Luc CHUM? CAR Annual Scientific Meeting Saturday, April 27 th 2013 Disclosure statement I do not have

More information

PET/CT in Lymphoma. FDG-avidity Staging (nodal & extra nodal) Response evaluation Early / interim Post-treatment Evaluation criteria

PET/CT in Lymphoma. FDG-avidity Staging (nodal & extra nodal) Response evaluation Early / interim Post-treatment Evaluation criteria Tuesday, August 28, 2012 Session 5, 11:30-12:10 PET/CT in Lymphoma FDG-avidity Staging (nodal & extra nodal) Response evaluation Early / interim Post-treatment Evaluation criteria Lymphoma Subtypes differ

More information

SBRT for oligometastases. new histology always needed?

SBRT for oligometastases. new histology always needed? Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger SBRT for oligometastases new histology always needed? Matthias Guckenberger Oligo-Metastases vs Oligo-Progression Oligo-metastasis

More information

2011 Pulmonary Pathology Society Biennial Meeting Program

2011 Pulmonary Pathology Society Biennial Meeting Program 2011 Pulmonary Pathology Society Biennial Meeting Program Thursday, August 18, 2011 7:00 AM Registration and Continental Breakfast 7:45 AM Welcome: Donald Guinee / Elisabeth Brambilla 8:00 AM Interstitial

More information

The Potential Clinical, Resource Use, and Fiscal Impacts of Lung-RADS to Inform Low-Dose CT Lung Cancer Screening in the United States

The Potential Clinical, Resource Use, and Fiscal Impacts of Lung-RADS to Inform Low-Dose CT Lung Cancer Screening in the United States The Potential Clinical, Resource Use, and Fiscal Impacts of Lung-RADS to Inform Low-Dose CT Lung Cancer in the United States Presenting Author: Joshua A. Roth, PhD, MHA 1,2 Co-Authors: Sean D. Sullivan,

More information

Medical Policy Number: R-9 Issue Date: September 2015 Responsible Department: Implementation Date: October 2015 Clinical Operations

Medical Policy Number: R-9 Issue Date: September 2015 Responsible Department: Implementation Date: October 2015 Clinical Operations National Imaging Associates, Inc. Clinical guideline PET SCAN CPT Code: 78811 - Limited area e.g. Chest, head/neck 78812 - Skull base to mid thigh 78813 - Whole Body 78814 With CT attenuation (Limited

More information

Leukemia and Lymphoma Overview

Leukemia and Lymphoma Overview Leukemia and Lymphoma Overview Michael Perry, M.D., M.S., M.A.C.P. University of Missouri/Ellis Fischel Cancer Center CALGB CRA Orientation, April 2008 For CALGB Participants Only Slide 1 Topics Acute

More information

Lung Cancer Consultant Outcomes Publication

Lung Cancer Consultant Outcomes Publication Lung Cancer Consultant Outcomes Publication Introduction This report describes the outcomes of individual consultant thoracic and cardiothoracic surgeons who carry out surgery for lung cancer. It has been

More information

Diagnostic Challenge. Department of Pathology,

Diagnostic Challenge. Department of Pathology, Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital

More information

LUNG CANCER. FCDS 2011 Educational Webcast Series November 17, 2011

LUNG CANCER. FCDS 2011 Educational Webcast Series November 17, 2011 LUNG CANCER FCDS 2011 Educational Webcast Series November 17, 2011 Judy Bonner, RN, MS, CTR and Lynne Pearson, CTR, LHRM Steven Peace, CTR Updated for 2011 Requirements and CSv02.03.02 1 Presentation Outline

More information

1 of 6 6/1/13 6:49 PM

1 of 6 6/1/13 6:49 PM A service of the U.S. National Institutes of Health Trial record 7 of 203 for: Melanoma Analysis Previous Study Return to List Next Study Expression Analysis of Specific Markers in Non-small Cell Lung

More information

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized

More information

Physicians Dissatisfied with Current Referral Process to Dentists

Physicians Dissatisfied with Current Referral Process to Dentists Physicians Dissatisfied with Current Referral Process to Dentists Authors: M. Beth Miloro, D.D.S.; Marko Vujicic, Ph.D. The Health Policy Institute (HPI) is a thought leader and trusted source for policy

More information

LUNG CANCER the new Staging System G.KIROVA TOKUDA HOSPITAL SOFIA

LUNG CANCER the new Staging System G.KIROVA TOKUDA HOSPITAL SOFIA LUNG CANCER the new Staging System G.KIROVA TOKUDA HOSPITAL SOFIA STAGING SYSTEM Provides standardized nomenclature for exchanging information Groups patients according to the biologic behavior of their

More information

Update on Benign and Malignant Hepatobiliary and Pancreatic Disease. Friday, Oct. 23 Saturday, Oct. 24, 2015 Seattle

Update on Benign and Malignant Hepatobiliary and Pancreatic Disease. Friday, Oct. 23 Saturday, Oct. 24, 2015 Seattle virginia mason continuing medical education Update on Benign and Malignant Hepatobiliary and Pancreatic Disease Friday, Oct. 23 Saturday, Oct. 24, 2015 Seattle Faculty course directors: Flavio G. Rocha,

More information

Diagnosis of Mesothelioma Pitfalls and Practical Information

Diagnosis of Mesothelioma Pitfalls and Practical Information Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com

More information

Developments in Biomarker Identification and Validation for Lung Cancer

Developments in Biomarker Identification and Validation for Lung Cancer Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options

More information

LUNG FIBROSIS FROM THE PATHOLOGIST S POINT OF VIEW THOMAS V. COLBY MD MAYO CLINIC IN ARIZONA

LUNG FIBROSIS FROM THE PATHOLOGIST S POINT OF VIEW THOMAS V. COLBY MD MAYO CLINIC IN ARIZONA LUNG FIBROSIS FROM THE PATHOLOGIST S POINT OF VIEW THOMAS V. COLBY MD MAYO CLINIC IN ARIZONA KEY POINTS: Not all fibrosis in the lung has the same clinical and prognostic implications. Fibroblastic proliferation

More information

PACIFIC PHYSICAL THERAPY 14650 Aviation Blvd., Suite 200 Manhattan Beach, CA 90250. Referring Doctor: PLEASE PRINT CLEARLY Email Address:

PACIFIC PHYSICAL THERAPY 14650 Aviation Blvd., Suite 200 Manhattan Beach, CA 90250. Referring Doctor: PLEASE PRINT CLEARLY Email Address: PACIFIC PHYSICAL THERAPY 14650 Aviation Blvd., Suite 200 Manhattan Beach, CA 90250 Date: Referring Doctor: PLEASE PRINT CLEARLY First Name: Last Name: Height: Address: City, St., Zip:_ Email Address: _

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

PhenoPath. Diagnoses you can count on BREAST. v.1

PhenoPath. Diagnoses you can count on BREAST. v.1 PhenoPath Diagnoses you can count on BREAST v.1 The use of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for determinination of prognostic and predictive markers require deep

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Introduction to Small Cell Lung Cancer: Prevalence, Initial Symptoms, Work-Up, and Staging

Introduction to Small Cell Lung Cancer: Prevalence, Initial Symptoms, Work-Up, and Staging Introduction to Small Cell Lung Cancer: Prevalence, Initial Symptoms, Work-Up, and Staging General Introduction to Small Cell Lung Cancer Lung cancer consists of two major types: small cell lung cancer

More information

A 70-year old Man with Pleural Effusion

A 70-year old Man with Pleural Effusion Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year

More information

HEPATO-PANCREATO- BILIARY (HPB) & STOMACH CANCER PROGRAM

HEPATO-PANCREATO- BILIARY (HPB) & STOMACH CANCER PROGRAM HEPATO-PANCREATO- BILIARY (HPB) & STOMACH CANCER PROGRAM UCSF Fresno Department of Surgery at Community Regional Medical Center 1.844.FOREGUT www.universitymds.com/foregutcancer HEPATO-PANCREATO-BILIARY

More information

Molecular Imaging and Prostate Cancer

Molecular Imaging and Prostate Cancer Molecular Imaging and Prostate Cancer Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. Based on rates from 2004 2006, the National Cancer Institute

More information

EVENING SPECIALTY CONFERENCE. Gynecological Pathology

EVENING SPECIALTY CONFERENCE. Gynecological Pathology EVENING SPECIALTY CONFERENCE Gynecological Pathology Case 1 Bojana Djordjevic, MD University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada Disclosure of Relevant Financial Relationships The USCAP

More information

Lung cancer: MTSS1 is a putative marker of tumour progression and metastatic disease

Lung cancer: MTSS1 is a putative marker of tumour progression and metastatic disease Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/lung-cancer-mtss1-is-a-putativemarker-of-tumour-progression-and-metastatic-disease/ Lung cancer: MTSS1 is a putative marker

More information

Pathology in HistoPathology. Dr. Meera Govindarajan R & D Histopath Lab Chennai

Pathology in HistoPathology. Dr. Meera Govindarajan R & D Histopath Lab Chennai Pathology in HistoPathology Dr. Meera Govindarajan R & D Histopath Lab Chennai When does that occur Report is not ready Report is vague Insufficient material or report is ambiguous Histopathology diagnosis

More information

Curie Scoring of MIBG Scans: A Prognostic Indicator

Curie Scoring of MIBG Scans: A Prognostic Indicator Curie Scoring of MIBG Scans: A Prognostic Indicator Marguerite T. Parisi, MD, MS Ed. Professor of Radiology and Pediatrics University of Washington Attending Radiologist, Seattle Children s Hospital, Seattle,

More information

What You Need to Know About Lung Cancer Immunotherapy

What You Need to Know About Lung Cancer Immunotherapy What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer

More information

General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014

General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014 General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention

More information